Hims & Hers Health (NYSE:HIMS) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Hims & Hers Health to “sell” from “hold,” adding to a mixed analyst backdrop that now includes an overall consensus rating of “Hold” and an average target price of $31.86.
• The company recently reported strong quarterly results, posting EPS of $0.08 versus the $0.02 estimate and revenue of $617.82 million, up 28.4% year over year, though revenue slightly missed expectations.
• Insider selling has been notable, with the CFO and another insider selling shares in recent months; in the last three months, insiders sold 204,857 shares worth about $5.29 million.

Hims & Hers Health (NYSE:HIMS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

Several other research firms also recently commented on HIMS. Morgan Stanley dropped their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday. Leerink Partners boosted their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a "market perform" rating in a research note on Monday, March 16th. Finally, JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health in a research note on Friday, April 24th. They set an "overweight" rating and a $35.00 target price for the company. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $31.86.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $28.46 on Friday. The company has a fifty day simple moving average of $22.56 and a two-hundred day simple moving average of $29.75. The company has a market cap of $6.49 billion, a price-to-earnings ratio of 55.81, a price-to-earnings-growth ratio of 3.50 and a beta of 2.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company's quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Oluyemi Okupe sold 36,922 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer owned 281,867 shares in the company, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider owned 8,752 shares of the company's stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 204,857 shares of company stock worth $5,285,706. 13.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock valued at $12,373,000 after acquiring an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the first quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its position in Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock valued at $47,000 after acquiring an additional 687 shares during the last quarter. Amundi lifted its position in Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company's stock valued at $489,000 after acquiring an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company's stock valued at $16,880,000 after acquiring an additional 29,471 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.